Are rates of gastrointestinal bleeding higher following the introduction of COX-2 inhibitors?

Expert Opinion on Drug Safety

Volumn 4, Issue 3, 2005, Pages 591-598

  Mamdani, Muhammad ^a  

^a INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

COX 2 inhibitors; Gastrointestinal (GI); Population; Safety

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; ROFECOXIB; VALDECOXIB;

ARTHRITIS; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DRUG DISTRIBUTION; DRUG MARKETING; DRUG SAFETY; DRUG UPTAKE; DUODENUM PERFORATION; DYSPEPSIA; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HOSPITAL ADMISSION; HUMAN; INFLAMMATION; LOW DRUG DOSE; PAIN; REVIEW; RISK REDUCTION; STOMACH OBSTRUCTION; STOMACH PERFORATION; UPPER GASTROINTESTINAL BLEEDING;

CYCLOOXYGENASE 2 INHIBITORS; EVIDENCE-BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMANS; INCIDENCE; INFLAMMATION; PAIN; POPULATION SURVEILLANCE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 19444384000     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.4.3.591     Document Type: Review

References (44)

1. BARAT I, ANDREASEN F, DAMSGAARD EMS: The consumption of drugs by 75-year-old individuals living in their own homes. Eur. J. Clin. Pharmacol. (2000) 56:501-509.
2. LAZZARONI M, BIANCHI PORRO G: Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations. Aliment. Pharmacol. Ther. (2004) 20(Suppl. 2):48-58.
3. PAULUS HE. FDA Arthritis Advisory Committee meeting: serious gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum. (1988) 31:1450-1451.
4. FELDMAN M, MCMAHON AT: Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal and-inflammatory drugs, with less gastrointestinal toxicity? Ann. Intern. Med. (2000) 132:134-143.
5. HAWKEY CJ: COX-2 inhibitors. Lancet (1999) 353:307-14.
6. BOMBARDIER C, LAINE L, REICIN A et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1520-1528.
7. SILVERSTEIN FE, FAICH G, GOLDSTEIN JL et al.: Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA (2000) 284:1247-1255.
8. SCHNITZER TJ, BURMESTER GR, MYSLER E et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet (2004) 364:665-674.
9. MAMDANI M, ROCHON P, JUURLINK DN et al.: Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. Br. Med. J. (2002) 325:624-627.
10. MACDONALD TM, MORANT SV, GOLDSTEIN JL, BURKE TA, PETTITT D: Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut (2003) 52:1265-1270.
11. IMS Health Canada Newsletter September 1999.
12. WRIGHT JM, PERRY TL, BASSETI KL, CHAMBERS GK: Reporting of 6-month versus 12-month data in a clinical trial of celecoxib. JAMA (2001) 286:2398-2400.
13. SILVERSTEIN F, SIMON L, FAICH G: Reporting of 6-month versus 12-month data in a clinical trial of celecoxib. In reply. JAMA (2001) 286:2399-2400
14. SINGH G, LANES S, TRIADAFILOPOULOS G: Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am. J. Med. (2004) 117:100-106.
15. CURTIS SP, LEE M, NG J et al.: Fewer upper-GI perforations, ulcers, and bleeds (PUBs) with etoricoxib than with non-selective cyclooxygenase inhibitors (NSAIDs). Ann. Rheum. Dis. (2002) 61:177.
16. GOLDSTEIN JL, KIVITZ AJ, VERBURG KM, RECKER DP, PALMER RC, Kent JD: A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment. Pharmacol. Ther. (2003) 18:125-132.
17. HUNT RH, HARPER S, WATSON DJ et al.: The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am. J. Gastroenterol. (2003) 98:1725-1733.
18. HENRY D, LIM LL, GARCIA RODRIGUEZ LA et al.: Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. Br. Med. J. (1996) 312:1563-1566.
19. JUNI P, RUTJES AWS, DIEPPE PA: Are the COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? Br. Med. J. (2002) 324:1287-1288.
20. WARNER TD, GIULIANO F, VOJNOVIC I, BUKASA A, MITCHELL JA, VANE JR: Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl Acad. Sci. USA (1999) 96:7563-7568.
21. BLAIN H, BOILEAU C, LAPICQUE F et al.: Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br. J. Clin. Pharmacol. (2002) 53:255-265.
22. HAWK ET, VINER JL, DANNENBERG A, DUBOIS RN: COX-2 in cancer - a player that's defining the rules. J. Natl. Cancer Inst. (2002) 94:545-546.
23. PATTI R, GUMIRED K, REDDANNA P, SUTTON LN, PHILLIPS PC, REDDY CD: Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. Cancer Lett. (2002) 180(1):13-21.
24. WASKEWICH C, BLUMENTHAL RD, LI H, STEIN R, GOLDENBERG DM, BURTON J: Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. (2002) 62:2029-2033.
25. BOUEE S, CHARLEMAGNE A, FAGNANI F et al.: Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy. Joint Bone Spine (2004) 71:214-220.
26. LELORIER J, FITZSIMON C, KERESTECI M, STEWART D, LAVOIE F: Drug utilization review of celecoxib in Ontario. Rheumatology (Oxford) (2003) 42(Suppl. 3):iii11-iii16.
27. CHAN FK, HUNG LC, SUEN BY et al.: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N. Engl. J. Med. (2002) 347:2104-2110.
28. SPIEGEL BM, TARGOWNIK L, DULAI GS, GRALNEK IM: The cost effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann. Intern. Med. (2003) 138:795-806.
29. MORIDE Y, DUCRUET T, ROCHON S, LAVOIE F: Persistency of use of COX-2-specific inhibitors and non-specific non-steroidal anti-inflammatory drugs (NSAIDs) in Quebec. Rheumatology (Oxford) (2003) 42(Suppl. 3):iii17-iii22.
30. ROTHMAN KJ, GREENLAND S: Modern epidemiology. Boston: Lippincott-Raven, 1998.
31. NORGARD B, PEDERSEN L, JOHNSEN SP et al.: COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study. Aliment. Pharmacol. Ther. (2004) 19:817-825.
32. LAPORTE JR, IBANEZ L, VIDAL X, VENDRELL L, LEONE R: Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. (2004) 27:411-420.
33. RUBIN DB: Estimating causal effects from large data sets using propensity scores. Ann. Intern. Med. (1997) 127:757-763.
34. BENSON K, HARTZ AJ: A comparison of observational studies and randomized, controlled trials. N. Engl. J. Med. (2000) 342:1878-1886.
35. GIRVIN B, RAFFERTY T, STEVENSON MR, JOHNSTON GD: Uptake of COX-2 selective inhibitors and influence on NSAID prescribing in Northern Ireland. Pharmacoepidemiol Drug Saf. (2004) 13:153-157.
36. MAMDANI M, ROCHON P, LAUPACIS A, ANDERSON G: Initial patterns of use of COX-2 inhibitors by elderly patients in Ontario: findings and implications. CMAJ (2002) 167:1125-1126.
37. HAWKEY CJ: COX-1 and COX-2 inhibitors. Best Pract. Res. Clin. Gastroenterol. (2001) 15:801-820.
38. MAMDANI M, JUURLINK DN, KOPP A, NAGLIE G, AUSTIN PC, LAUPACIS A: Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study. Br. Med. J. (2004) 328:1415-1416.
39. WEBER A, CASINI A, HEINE A et al.: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. (2004) 47:550-557.
40. SUPURAN CT, CASINI A, MASTROLORENZO A, SCOZZAFAVA A: COX-2 selective inhibitors, carbonic anhydrase inhibition and anticancer properties of sulfonamides belonging to this class of pharmacological agents. Mini Rev. Med. Chem. (2004) 4:625-632.
41. PUSCAS I, COLTAU M, PASCA R: Nonsteroidal anti-inflammatory drugs activate carbonic anhydrase by a direct mechanism of action. J. Pharmacol. Exp. Ther. (1996) 277:1464-1466.
42. PUSCAS I: Treatment of gastroduodenal ulcers with carbonic anhydrase inhibitors. Ann. NY Acad. Sci. (1984) 429:426-431.
43. PUSCAS I, COLTAU M, BAICAN M, PASCA R, DOMUTA G, HECHT A: Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action. Drugs Exp. Clin. Res. (2001) 27:53-60.
44. TOPOL EJ: Arthritis medicines and cardiovascular events - 'house of coxibs'. JAMA (2005) 293:366-368.